2011
DOI: 10.1016/j.bmcl.2010.10.082
|View full text |Cite
|
Sign up to set email alerts
|

3-[Benzimidazo- and 3-[benzothiadiazoleimidazo-(1,2-c)quinazolin-5-yl]-2H-chromene-2-ones as potent antimicrobial agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
40
0
1

Year Published

2011
2011
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 81 publications
(41 citation statements)
references
References 32 publications
0
40
0
1
Order By: Relevance
“…Cellulose sulfuric acid (Catalyst)/ DMF MWI (5-6 min, 91-97%) Antibacterial and antifungal [66] 9-Aryl-6-chloropurines (59) Trimethylorthoformate in acetic anhydride (MWI, 120 °C, 1 h).…”
Section: -[Benzimidazo(12-c)quinazolin-5-yl]-2h-chromene-2-one (57)mentioning
confidence: 99%
“…Cellulose sulfuric acid (Catalyst)/ DMF MWI (5-6 min, 91-97%) Antibacterial and antifungal [66] 9-Aryl-6-chloropurines (59) Trimethylorthoformate in acetic anhydride (MWI, 120 °C, 1 h).…”
Section: -[Benzimidazo(12-c)quinazolin-5-yl]-2h-chromene-2-one (57)mentioning
confidence: 99%
“…FDA has approved several quinazoline derivatives as anticancer drugs, such as Gefitinib, Erlotinib, Lapatinib and Vandetanib 9 . Moreover, a series of triazol-4-ylsubstituted quinazolines and 2-thio- [1,2,4]triazolo [1,5-c]quinazoline derivatives have been identified as potent antimicrobial agents 27 . Therefore, the development of a novel and efficient anticancer agent that can be used for prophylaxis as well as the treatment of bacterial infections in cancer patients remains an important goal in medicinal chemistry.…”
Section: Introductionmentioning
confidence: 99%
“…The current interest in 4H-chromene derivatives arises from their potential application as antimicrobial (Kuarm et al, 2011;Rai et al, 2010), anti-HIV (Bhavsar et al, 2011;Park et al, 2008), anti tubercular (Kamdar et al, 2010), antioxidant (Singh et al, 2010), anticancer (Raju et al, 2011), antitumor (Huang et al, 2009), cytotoxic agent (Raj et al, 2010;Sabry et al, 2011), antidyslipidemic agent (Sashidhara et al, 2008), antileishmanial (Nazarian et al, 2010), anti inflametory (Gebhardt et al, 2007), antihelicobacter pylori agent (Chimenti et al, 2007), and TNF-a inhibitor (Cheng et al, 2003).…”
Section: Introductionmentioning
confidence: 99%